- Home
- APLT
as 03-25-2025 10:30am EST
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 80.3M | IPO Year: | 2019 |
| Target Price: | $6.10 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.43 - $10.62 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -94.36% | Revenue Growth (next year): | 2426.33% |
Stock Insider Trading Activity of Applied Therapeutics Inc. (APLT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Funtleyder Leslie D. | APLT | See Remarks | Mar 4 '25 | Sell | $0.44 | 14,502 | $6,380.88 | 390,459 | |
| Chinoporos Constantine | APLT | See Remarks | Mar 4 '25 | Sell | $0.44 | 447 | $196.68 | 271,436 | |
| Perfetti Riccardo | APLT | Chief Medical Officer | Mar 4 '25 | Sell | $0.44 | 10,366 | $4,561.04 | 890,409 | |
| Funtleyder Leslie D. | APLT | See Remarks | Feb 6 '25 | Sell | $0.61 | 22,950 | $13,999.50 | 390,459 | |
| Chinoporos Constantine | APLT | See Remarks | Feb 6 '25 | Sell | $0.61 | 28,117 | $17,151.37 | 271,436 | |
| Perfetti Riccardo | APLT | Chief Medical Officer | Feb 6 '25 | Sell | $0.61 | 86,078 | $52,507.58 | 890,409 |
Latest Applied Therapeutics Inc. News
APLT Breaking Stock News: Dive into APLT Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
Simply Wall St.
14 days ago
3 Penny Stocks With At Least $50M Market Cap
Clinical Trials Arena
a month ago
Why pharma is still far from a treatment for galactosemia
Zacks
a month ago
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?
GlobeNewswire
2 months ago
Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality
Insider Monkey
3 months ago
Is Applied Therapeutics (APLT) the Best Penny Stock to Invest In According to Media?
Insider Monkey
3 months ago
Here’s Why Applied Therapeutics, Inc. (NASDAQ:APLT) Is Among the Best Diabetes Stocks to Buy Under $10
MT Newswires
3 months ago
William Blair Downgrades Applied Therapeutics to Market Perform From Outperform
Compare APLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLT Applied Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.